Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-2

Pralmorelin, Growth Hormone Releasing Peptide-2, KP-102

Quick Stats
Studies 230
Trials 1
Score 3
2004 pubmed

Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats.

Granado. Miriam M; Priego. Teresa T; Martín. Ana I AI; Villanúa. M Angeles MA; López-Calderón. Asunción A

Key Findings

  • Arthritic rats given GHRP‑2 showed lower arthritis scores and reduced paw swelling.
  • Serum IL‑6 and nitrite/nitrate levels, which rise with inflammation, were significantly decreased after GHRP‑2 treatment.
  • Both GHRP‑2 and natural ghrelin directly suppressed IL‑6 release from cultured macrophages, indicating a receptor‑mediated anti‑inflammatory effect.

Practical Outcomes

  • For self‑experimenters, this suggests GHRP‑2 might have anti‑inflammatory benefits beyond its growth‑hormone‑releasing properties. However, the data are from a rat model, so human dosing, safety, and efficacy remain uncertain. If considering GHRP‑2 for inflammation, start with very low doses, monitor inflammatory markers, and be aware that benefits seen in animals may not translate directly to people.

Summary

In rats with arthritis, daily injections of the ghrelin‑like peptide GHRP‑2 reduced joint swelling, lowered inflammatory markers like IL‑6, and helped restore leptin levels, showing it can act as an anti‑inflammatory agent even though it didn’t boost food intake in the sick animals.

Abstract

Chronic arthritis induces hypermetabolism and cachexia. Ghrelin is a gastrointestinal hormone that has been proposed as a treatment to prevent cachexia. The aim of this work was to examine the effect of administration of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) to arthritic rats. Male Wistar rats were injected with Freund's adjuvant, and 15 days later arthritic and control rats were daily injected with GHRP-2 (100 microg/kg) or with saline for 8 days. Arthritis induced an increase in serum ghrelin (P < 0.01) and a decrease in serum concentrations of leptin (P < 0.01), whereas GHRP-2 administration increased serum concentrations of leptin. GHRP-2 increased food intake in control rats but not in arthritic rats. However, in arthritic rats GHRP-2 administration ameliorated the external symptoms of arthritis, as it decreased the arthritis score (10.4 +/- 0.8 vs. 13.42 +/- 0.47, P < 0.01) and the paw volume. In addition, circulating IL-6 and nitrites/nitrates were increased by arthritis, and GHRP-2 treatment decreased the serum IL-6 levels (P < 0.01). To elucidate whether GHRP-2 is able to modulate IL-6 release directly on immune cells, peritoneal macrophage cultures were incubated with GHRP-2 or ghrelin, the endogenous ligand of the growth hormone (GH) secretagogue receptor. Both GHRP-2 (10(-7) M) and ghrelin (10(-7) M) prevented endotoxin-induced IL-6 and decreased nitrite/nitrate release from peritoneal macrophages in vitro. These data suggest that GHRP-2 administration has an anti-inflammatory effect in arthritic rats that seems to be mediated by ghrelin receptors directly on immune cells.

Study Information

Provider

pubmed

Year

2004

Date

2004-10-26T00:00:00.000Z

DOI

10.1152/ajpendo.00196.2004